Browsing Tag
Basal Cell Carcinoma
4 posts
Invion (ASX: IVX) just unlocked the door to 80% of skin cancers — here is what the data shows so far
Invion Limited (ASX: IVX) advances INV043 into basal cell carcinoma after second positive SCC data set. Read what this means for the trial and the company. →
Why clinicians are watching SkinJect as a potential alternative to repeated Mohs surgery
Find out how SkinJect could challenge repeated Mohs surgery and reshape basal cell carcinoma care. Read the full analysis now.
Could intratumoral peptide immunotherapy alter first-line thinking in basal cell carcinoma?
Could VP-315 reshape first-line basal cell carcinoma treatment? Read the executive analysis on strategy, competition, and commercial risks.
Verrica’s SITC reveal: can VP-315’s immune activation data reshape the skin cancer treatment landscape
Find out how Verrica’s VP-315 immune activation data at SITC 2025 could redefine non-surgical skin cancer treatment options for dermatologic oncology.